The risk and management of latent tuberculosis infection reactivation in patients with inflammatory bowel disease using biological agents and small molecule agents
10.3760/cma.j.cn101480-20220409-00057
- VernacularTitle:炎症性肠病患者应用生物制剂和小分子制剂发生潜伏结核感染再激活风险现状和应对
- Author:
Haozheng LIANG
1
;
Gechong RUAN
1
;
Xiaotian CHU
1
;
Hong YANG
1
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院消化内科，北京 100730
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Biological agents;
Small molecule agents;
Latent tuberculosis infection
- From:
Chinese Journal of Inflammatory Bowel Diseases
2023;07(1):55-59
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is a kind of chronic inflammatory immune disease of the intestine. In recent years, biologics and small molecule agents with different targets have been used for the treatment of IBD. However, it also brings concerns about opportunistic infections, among which the reactivation of latent tuberculosis infection is more harmful. China is still one of the epidemic areas of tuberculosis, and clinicians attach great importance to the reactivation of latent tuberculosis infection induced by biologics and small molecule agents. This paper reviews the risk of latent tuberculosis infection reactivation associated with biologics and small molecule agents and the recommendation of the guideline. It is expected to provide a reference for the application of these medications in patients with inflammatory bowel disease complicated by latent tuberculosis infection.
